Evidence map›Paper›PMID 35254896›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

Restriction of viral gene expression and replication prevents immortalization of human keratinocytes by a beta-human papillomavirus.

Tina M Rehm, Elke Straub, Thomas Iftner, Frank Stubenrauch

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. A splice donor inJournal of virology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tina M RehmInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, D72076 Tuebingen, Germany.ORCID 0000-0002-4763-7303
Elke StraubInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, D72076 Tuebingen, Germany.
Thomas IftnerInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, D72076 Tuebingen, Germany.ORCID 0000-0002-5929-7078
Frank StubenrauchInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, D72076 Tuebingen, Germany.ORCID 0000-0002-6685-299X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SignificanceHigh-risk (HR) human papillomaviruses (HPV) from the genus alpha cause anogenital and oropharyngeal cancers, whereas the contribution of HPV from the genus beta to the development of cutaneous squamous cell cancer is still under debate. HR-HPV genomes display potent immortalizing activity in human keratinocytes, the natural target cell for HPV. This paper shows that immortalization of keratinocytes by the beta-HPV49 genome requires the inactivation of the viral E8^E2 repressor protein and the presence of the E6 and E7 oncoproteins but also of the E1 and E2 replication proteins. This reveals important differences in the carcinogenic properties of HR-HPV and beta-HPV but also warrants further investigations on the distribution and mutation frequencies of beta-HPV in human cancers.

Indexed as

Gene Expression Regulation, ViralHost-Pathogen InteractionsVirus ReplicationBetapapillomavirusCell Line, TransformedGenome, ViralHumansKeratinocytesOncogene Proteins, ViralPapillomavirus InfectionsRNA, ViralOncogene Proteins, ViralRNA, Viralbeta-human papillomaviruscutaneous squamous cell cancerE8^E2immortalization

Identifiers

PMID35254896
PMCPMC8931373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.